MET
43 programs · 40 companies
Programs
43
Companies
40
Active Trials
26
Targeting MET
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| SNY-5783 | Sanofi | Phase 1/2 | SLEAlzheimer's | |
| Sotosacituzumab | Vertex Pharma | Phase 1 | ALL | |
| RVM-274 | Revolution Medicines | Phase 3 | IPFALL | |
| Talazasiran | Kymera | NDA/BLA | HSNB | |
| RAP-2478 | Rapport Ther | Phase 3 | PBC | |
| Mavuzasiran | Protagonist | Phase 3 | Rett | |
| NIA-IIT-413 | NIAID | Phase 2 | MDD | |
| EOR-IIT-377 | EORTC | Phase 2/3 | CSU | |
| HOR-3482 | Horizon (Amgen) | Phase 3 | SMAPsoriasis | |
| VES-7360 | Vesalius Ther | Approved | LNEwing Sarcoma | |
| MET-3015 | Metsera | Preclinical | MCL | |
| MBX-6478 | MBX Bio | Phase 1/2 | TTR AmyloidosisNSCLC | |
| Tixazasiran | Kitov Pharma | Phase 1 | NASHMelanoma | |
| TES-8356 | Tesaro (GSK) | NDA/BLA | Ewing Sarcoma | |
| LAE-436 | Laekna | Preclinical | WMMelanoma | |
| Elracapivasertib | SK Bioscience | Preclinical | RBLGS | |
| KAR-4449 | Kartos | Phase 2 | MCLBreast Ca | |
| Pemicilimab | Kodiak Sci | Phase 2 | WMCervical Ca | |
| FRE-IIT-649 | Fred Hutch | Phase 3 | Prostate Ca | |
| MAS-IIT-645 | Mass General | Phase 1 | Melanoma | |
| RYT-8232 | Rhythm Pharma | Phase 2/3 | Wilms | |
| CYM-2446 | CymaBay (Gilead) | Phase 2/3 | EoEPsoriasis | |
| Tirazanubrutinib | CymaBay (Gilead) | NDA/BLA | SchizophreniaNB | |
| Capicilimab | Silence Ther | Phase 2/3 | NSCLCHNSCC | |
| Sovalemzoparlimab | Y-Biologics | Phase 2/3 | WM | |
| Ribotapinarof | Zydus Life | NDA/BLA | CholangiocarcinomaRett | |
| Zoriosocimab | Glenmark Pharma | Phase 3 | MCCNSCLC | |
| NOX-4885 | Noxopharm | NDA/BLA | MDS | |
| Fixabrutinib | Polyphor | Phase 1 | FSGSRB | |
| Pexasertib | Nuevolution (Amgen) | Approved | ADPKD | |
| Rilutapinarof | Nuevolution (Amgen) | Phase 1 | Parkinson'sObesity | |
| CYA-8318 | Celyad Oncology | Preclinical | GAEndometrial Ca | |
| IPC-884 | IPCA Labs | Approved | MDSNMOSD | |
| HYP-6536 | Hypera Pharma | Preclinical | MCCPBC | |
| Talatenlimab | Pharmaniaga | Approved | SCD | |
| Lisotuximab | SPIMACO | Phase 1 | PBCDravet | |
| NOB-8652 | Nobel Ilac | Approved | WMSchizophrenia | |
| ASP-8946 | Aspen Global | Phase 1 | MDSGIST | |
| ASA-IIT-788 | Asan Medical Center | NDA/BLA | PNH | |
| ASA-IIT-544 | Asan Medical Center | Phase 1/2 | MG | |
| 002-6973 | Kelun Pharma | Approved | RCCNSCLC | |
| 299-6118 | Cellid | Phase 1/2 | Melanoma | |
| 453-4569 | Santen Pharma | Phase 2/3 | Parkinson's |